Ingenix
Builds AI architecture fusing biological data modalities to accelerate pharma and biotech drug development
€13MSeed+
Role not disclosedSP
Sofinnova Partners
Activity from announced rounds
Activity in this selectionEurope · Seed
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $28.2M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSignadori Bio
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
€11.1MSeed+
Role not disclosed